James N Kochenderfer, Mark E Dudley, Sadik H Kassim, Robert P T Somerville, Robert O Carpenter, Maryalice Stetler-Stevenson, James C Yang, Giao Q Phan, Marybeth S Hughes, Richard M Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F Li, Lien T Ngo, Andre Goy, Tatyana Feldman, David E Spaner, Michael L Wang, Clara C Chen, Sarah M Kranick, Avindra Nath, Debbie-Ann N Nathan, Kathleen E Morton, Mary Ann Toomey, Steven A Rosenberg
PURPOSE: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19(+) B-cell malignancies. PATIENTS AND METHODS: We treated 15 patients with advanced B-cell malignancies. Nine patients had diffuse large B-cell lymphoma (DLBCL), two had indolent lymphomas, and four had chronic lymphocytic leukemia. Patients received a conditioning chemotherapy regimen of cyclophosphamide and fludarabine followed by a single infusion of anti-CD19 CAR T cells...
February 20, 2015: Journal of Clinical Oncology